Germinal center-dependent and -independent immune responses of tumor-infiltrating B cells in human cancers.
antibody
cancer
germinal center
plasma cell
tertiary lymphoid structure
Journal
Cellular & molecular immunology
ISSN: 2042-0226
Titre abrégé: Cell Mol Immunol
Pays: China
ID NLM: 101242872
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
11
02
2023
accepted:
14
06
2023
medline:
1
9
2023
pubmed:
8
7
2023
entrez:
7
7
2023
Statut:
ppublish
Résumé
B cells play essential roles in immunity, mainly through the production of high affinity plasma cells (PCs) and memory B (Bmem) cells. The affinity maturation and differentiation of B cells rely on the integration of B-cell receptor (BCR) intrinsic and extrinsic signals provided by antigen binding and the microenvironment, respectively. In recent years, tumor infiltrating B (TIL-B) cells and PCs (TIL-PCs) have been revealed as important players in antitumor responses in human cancers, but their interplay and dynamics remain largely unknown. In lymphoid organs, B-cell responses involve both germinal center (GC)-dependent and GC-independent pathways for Bmem cell and PC production. Affinity maturation of BCR repertoires occurs in GC reactions with specific spatiotemporal dynamics of signal integration by B cells. In general, the reactivation of high-affinity Bmem cells by antigens triggers GC-independent production of large numbers of PC without BCR rediversification. Understanding B-cell dynamics in immune responses requires the integration of multiple tools and readouts such as single-cell phenotyping and RNA-seq, in situ analyses, BCR repertoire analysis, BCR specificity and affinity assays, and functional tests. Here, we review how those tools have recently been applied to study TIL-B cells and TIL-PC in different types of solid tumors. We assessed the published evidence for different models of TIL-B-cell dynamics involving GC-dependent or GC-independent local responses and the resulting production of antigen-specific PCs. Altogether, we highlight the need for more integrative B-cell immunology studies to rationally investigate TIL-B cells as a leverage for antitumor therapies.
Identifiants
pubmed: 37419983
doi: 10.1038/s41423-023-01060-7
pii: 10.1038/s41423-023-01060-7
pmc: PMC10468534
doi:
Substances chimiques
Receptors, Antigen, B-Cell
0
Antigens
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1040-1050Informations de copyright
© 2023. The Author(s).
Références
Attaf N, Baaklini S, Binet L & Milpied P. Heterogeneity of germinal center B cells: New insights from single-cell studies. Eur J Immunol. 2021. https://doi.org/10.1002/eji.202149235 .
Cyster JG, Allen CDCB. Cell responses: cell interaction dynamics and decisions. Cell. 2019;177:524–40.
pubmed: 31002794
pmcid: 6538279
doi: 10.1016/j.cell.2019.03.016
Victora GD, Nussenzweig MC. Germinal centers. Annu Rev Immunol. 2022;40:413–42.
pubmed: 35113731
doi: 10.1146/annurev-immunol-120419-022408
Apoptosis and antigen affinity limit effector cell differentiation of a single naïve B cell. Science. 2015. https://www.science.org/doi/10.1126/science.aaa1342 .
Roco JA, Mesin L, Binder SC, Nefzger C, Gonzalez-Figueroa P, Canete PF, et al. Class switch recombination occurs infrequently in germinal centers. Immunity. 2019;51:337–.e7.
pubmed: 31375460
pmcid: 6914312
doi: 10.1016/j.immuni.2019.07.001
Sundling C, Lau A, Bourne K, Young C, Laurianto C, Hermes JR, et al. Positive selection of IgG+ over IgM+ B cells in the germinal center reaction. Immunity. 2021;54:988–1001.e5.
pubmed: 33857421
doi: 10.1016/j.immuni.2021.03.013
Mesin L, Schiepers A, Ersching J, Barbulescu A, Cavazzoni CB, Angelini A, et al. Restricted clonality and limited germinal center reentry characterize memory B cell reactivation by boosting. Cell. 2020;180:92–106.e11.
pubmed: 31866068
pmcid: 6958527
doi: 10.1016/j.cell.2019.11.032
Gregoire C, Spinelli L, Villazala-Merino S, Gil L, Holgado MP, Moussa M, et al. Viral infection engenders bona fide and bystander subsets of lung-resident memory B cells through a permissive mechanism. Immunity. 2022;55:1216–.e9.
pubmed: 35768001
pmcid: 9396418
doi: 10.1016/j.immuni.2022.06.002
MacLean AJ, Richmond N, Koneva L, Attar M, Medina C, Thornton EE, et al. Secondary influenza challenge triggers resident memory B cell migration and rapid relocation to boost antibody secretion at infected sites. Immunity. 2022;55:718–.e8.
pubmed: 35349789
pmcid: 9044924
doi: 10.1016/j.immuni.2022.03.003
Fridman WH, Petitprez F, Meylan M, Chen TW, Sun CM, Roumenina LT, et al. B cells and cancer: to B or not to B? J Exp Med. 2021;218:e20200851.
pubmed: 33601413
doi: 10.1084/jem.20200851
Domblides C, Rochefort J, Riffard C, Panouillot M, Lescaille G, Teillaud JL, et al. Tumor-associated tertiary lymphoid structures: from basic and clinical knowledge to therapeutic manipulation. Front Immunol 2021;12:698604.
pubmed: 34276690
pmcid: 8279885
doi: 10.3389/fimmu.2021.698604
Sautès-Fridman C, Verneau J, Sun CM, Moreira M, Chen TW, Meylan M, et al. Tertiary lymphoid structures and B cells: clinical impact and therapeutic modulation in cancer. Semin Immunol. 2020;48:101406.
pubmed: 33248905
doi: 10.1016/j.smim.2020.101406
Sautès-Fridman C, Lawand M, Giraldo NA, Kaplon H, Germain C, Fridman WH, et al. Tertiary lymphoid structures in cancers: prognostic value, regulation, and manipulation for therapeutic intervention. Front Immunol. 2016;7:407.
Laumont CM, Banville AC, Gilardi M, Hollern DP, Nelson BH. Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities. Nat Rev Cancer. 2022;22:414–30.
pubmed: 35393541
pmcid: 9678336
doi: 10.1038/s41568-022-00466-1
Schumacher TN, Thommen DS. Tertiary lymphoid structures in cancer. Science. 2022;375:eabf9419.
pubmed: 34990248
doi: 10.1126/science.abf9419
Italiano A, Bessede A, Pulido M, Bompas E, Piperno-Neumann S, Chevreau C, et al. Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort. Nat Med 2022;28:1199–206.
pubmed: 35618839
doi: 10.1038/s41591-022-01821-3
Petitprez F, de Reyniès A, Keung EZ, Chen TW, Sun CM, Calderaro J, et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature. 2020;577:556–60.
pubmed: 31942077
doi: 10.1038/s41586-019-1906-8
Vanhersecke L, Brunet M, Guégan JP, Rey C, Bougouin A, Cousin S, et al. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat. Cancer. 2021;1–9 https://doi.org/10.1038/s43018-021-00232-6 .
Patil NS, Nabet BY, Müller S, Koeppen H, Zou W, Giltnane J, et al. Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer. Cancer Cell. 2022;S1535610822000356 https://doi.org/10.1016/j.ccell.2022.02.002 .
Ng KW, Boumelha J, Enfield KSS, Almagro J, Cha H, Pich O, et al. Antibodies against endogenous retroviruses promote lung cancer immunotherapy. Nature. 2023;1–11 https://doi.org/10.1038/s41586-023-05771-9 .
Germain C, Gnjatic S, Tamzalit F, Knockaert S, Remark R, Goc J, et al. Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am J Respir Crit Care Med 2014;189:832–44.
pubmed: 24484236
doi: 10.1164/rccm.201309-1611OC
Milpied P, Cervera-Marzal I, Mollichella ML, Tesson B, Brisou G, Traverse-Glehen A, et al. Human germinal center transcriptional programs are de-synchronized in B cell lymphoma. Nat Immunol. 2018;19:1013–24.
pubmed: 30104629
doi: 10.1038/s41590-018-0181-4
Victora GD, Dominguez-Sola D, Holmes AB, Deroubaix S, Dalla-Favera R, Nussenzweig MC. Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas. Blood. 2012;120:2240–8.
pubmed: 22740445
pmcid: 3447782
doi: 10.1182/blood-2012-03-415380
King HW, Orban N, Riches JC, Clear AJ, Warnes G, Teichmann SA, et al. Single-cell analysis of human B cell maturation predicts how antibody class switching shapes selection dynamics. Sci Immunol. 2021;6:eabe6291.
Lambrechts D, Wauters E, Boeckx B, Aibar S, Nittner D, Burton O, et al. Phenotype molding of stromal cells in the lung tumor microenvironment. Nat Med. 2018;24:1277–89.
pubmed: 29988129
doi: 10.1038/s41591-018-0096-5
Qian J, Olbrecht S, Boeckx B, Vos H, Laoui D, Etlioglu E, et al. A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling. Cell Res. 2020;30:745–62.
pubmed: 32561858
pmcid: 7608385
doi: 10.1038/s41422-020-0355-0
Hao D, Han G, Sinjab A, Gomez-Bolanos LI, Lazcano R, Serrano A, et al. The single-cell immunogenomic landscape of B and plasma cells in early-stage lung adenocarcinoma. Cancer Discov. 2022;12:2626–45.
pubmed: 36098652
pmcid: 9633381
doi: 10.1158/2159-8290.CD-21-1658
Massoni-Badosa, R et al. An atlas of cells in the human tonsil. 2022.06.24.497299. Preprint at https://doi.org/10.1101/2022.06.24.497299 (2022).
Corinaldesi C, Holmes AB, Shen Q, Grunstein E, Pasqualucci L, Dalla-Favera R, et al. Tracking immunoglobulin repertoire and transcriptomic changes in germinal center B cells by single-cell analysis. Front Immunol. 2022;12:818758.
Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020;577:561–5.
pubmed: 31942071
doi: 10.1038/s41586-019-1914-8
Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577:549–55.
pubmed: 31942075
pmcid: 8762581
doi: 10.1038/s41586-019-1922-8
Siliņa K, Soltermann A, Attar FM, Casanova R, Uckeley ZM, Thut H, et al. Germinal centers determine the prognostic relevance of tertiary lymphoid structures and are impaired by corticosteroids in lung squamous cell carcinoma. Cancer Res. 2018;78:1308–20.
pubmed: 29279354
doi: 10.1158/0008-5472.CAN-17-1987
Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17:218.
pubmed: 27765066
pmcid: 5073889
doi: 10.1186/s13059-016-1070-5
Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37:773–82.
pubmed: 31061481
pmcid: 6610714
doi: 10.1038/s41587-019-0114-2
Bolotin DA, Poslavsky S, Mitrophanov I, Shugay M, Mamedov IZ, Putintseva EV, et al. MiXCR: software for comprehensive adaptive immunity profiling. Nat Methods. 2015;12:380–1.
pubmed: 25924071
doi: 10.1038/nmeth.3364
Song L, Cohen D, Ouyang Z, Cao Y, Hu X, Liu XS. TRUST4: immune repertoire reconstruction from bulk and single-cell RNA-seq data. Nat Methods. 2021;18:627–30.
pubmed: 33986545
pmcid: 9328942
doi: 10.1038/s41592-021-01142-2
Rao A, Barkley D, França GS, Yanai I. Exploring tissue architecture using spatial transcriptomics. Nature. 2021;596:211–20.
pubmed: 34381231
pmcid: 8475179
doi: 10.1038/s41586-021-03634-9
Kleshchevnikov V, Shmatko A, Dann E, Aivazidis A, King HW, Li T, et al. Cell2location maps fine-grained cell types in spatial transcriptomics. Nat Biotechnol. 2022;40:661–71.
pubmed: 35027729
doi: 10.1038/s41587-021-01139-4
Engblom C, et al. Spatial transcriptomics of T and B cell receptors uncovers lymphocyte clonal dynamics in human tissue. 2022.11.22.516865 Preprint at https://doi.org/10.1101/2022.11.22.516865 (2022).
Liu S, Iorgulescu JB, Li S, Borji M, Barrera-Lopez IA, Shanmugam V, et al. Spatial maps of T cell receptors and transcriptomes reveal distinct immune niches and interactions in the adaptive immune response. Immunity. 2022;55:1940–.e5.
pubmed: 36223726
doi: 10.1016/j.immuni.2022.09.002
Laughney AM, Hu J, Campbell NR, Bakhoum SF, Setty M, Lavallée VP, et al. Regenerative lineages and immune-mediated pruning in lung cancer metastasis. Nat Med. 2020;26:259–69.
pubmed: 32042191
pmcid: 7021003
doi: 10.1038/s41591-019-0750-6
Kim N, Kim HK, Lee K, Hong Y, Cho JH, Choi JW, et al. Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. Nat Commun. 2020;11:2285.
pubmed: 32385277
pmcid: 7210975
doi: 10.1038/s41467-020-16164-1
Wieland A, Patel MR, Cardenas MA, Eberhardt CS, Hudson WH, Obeng RC et al. Defining HPV-specific B cell responses in patients with head and neck cancer. Nature. 2020. https://doi.org/10.1038/s41586-020-2931-3 .
Ruffin AT, Cillo AR, Tabib T, Liu A, Onkar S, Kunning SR, et al. B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma. Nat Commun. 2021;12:3349.
pubmed: 34099645
pmcid: 8184766
doi: 10.1038/s41467-021-23355-x
Mauri C, Menon M. Human regulatory B cells in health and disease: therapeutic potential. J Clin Investig. 2017;127:772–9.
pubmed: 28248202
pmcid: 5330739
doi: 10.1172/JCI85113
Shen P, Roch T, Lampropoulou V, O'Connor RA, Stervbo U, Hilgenberg E, et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature. 2014;507:366–70.
pubmed: 24572363
pmcid: 4260166
doi: 10.1038/nature12979
Michaud D, Steward CR, Mirlekar B, Pylayeva-Gupta Y. Regulatory B cells in cancer. Immunol Rev. 2021;299:74–92.
pubmed: 33368346
doi: 10.1111/imr.12939
Mirlekar B, Wang Y, Li S, Zhou M, Entwistle S, De Buysscher T, et al. Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity. Cell Rep Med. 2022;3:100744.
pubmed: 36099917
pmcid: 9512696
doi: 10.1016/j.xcrm.2022.100744
Mirlekar B, Michaud D, Lee SJ, Kren NP, Harris C, Greene K, et al. B cell–derived IL35 drives STAT3-dependent CD8+ T-cell exclusion in pancreatic cancer. Cancer Immunol Res. 2020;8:292–308.
pubmed: 32024640
pmcid: 7056532
doi: 10.1158/2326-6066.CIR-19-0349
Hu Q, Hong Y, Qi P, Lu G, Mai X, Xu S, et al. Atlas of breast cancer infiltrated B-lymphocytes revealed by paired single-cell RNA-sequencing and antigen receptor profiling. Nat Commun. 2021;12:2186.
pubmed: 33846305
pmcid: 8042001
doi: 10.1038/s41467-021-22300-2
Glass MC, Glass DR, Oliveria JP, Mbiribindi B, Esquivel CO, Krams SM, et al. Human IL-10-producing B cells have diverse states that are induced from multiple B cell subsets. Cell Rep. 2022;39:110728.
pubmed: 35443184
pmcid: 9107325
doi: 10.1016/j.celrep.2022.110728
Sautès-Fridman C, Petitprez F, Calderaro J, Fridman WH. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019;19:307–25.
pubmed: 31092904
doi: 10.1038/s41568-019-0144-6
Werner F, Wagner C, Simon M, Glatz K, Mertz KD, Läubli H, et al. A standardized analysis of tertiary lymphoid structures in human melanoma: disease progression- and tumor site-associated changes with germinal center alteration. Front Immunol. 2021;12:675146.
pubmed: 34248957
pmcid: 8264652
doi: 10.3389/fimmu.2021.675146
Thibult M-L, Mamessier E, Gertner-Dardenne J, Pastor S, Just-Landi S, Xerri L, et al. PD-1 is a novel regulator of human B-cell activation. Int Immunol. 2013;25:129–37.
pubmed: 23087177
doi: 10.1093/intimm/dxs098
Wang X, Wang G, Wang Z, Liu B, Han N, Li J, et al. PD-1-expressing B cells suppress CD4+ and CD8+ T cells via PD-1/PD-L1-dependent pathway. Mol Immunol. 2019;109:20–26.
pubmed: 30851633
doi: 10.1016/j.molimm.2019.02.009
Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci. 2001;98:13866–71.
pubmed: 11698646
pmcid: 61133
doi: 10.1073/pnas.231486598
Xiao X, Lao XM, Chen MM, Liu RX, Wei Y, Ouyang FZ, et al. PD-1hi identifies a novel regulatory B-cell population in human hepatoma that promotes disease progression. Cancer Discov. 2016;6:546–59.
pubmed: 26928313
doi: 10.1158/2159-8290.CD-15-1408
Thommen DS, Koelzer VH, Herzig P, Roller A, Trefny M, Dimeloe S, et al. A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat Med. 2018;24:994–1004.
pubmed: 29892065
pmcid: 6110381
doi: 10.1038/s41591-018-0057-z
Rodriguez AB, Peske JD, Woods AN, Leick KM, Mauldin IS, Meneveau MO, et al. Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts. Cell Rep. 2021;36:109422.
pubmed: 34289373
pmcid: 8362934
doi: 10.1016/j.celrep.2021.109422
Hollern DP, Xu N, Thennavan A, Glodowski C, Garcia-Recio S, Mott KR, et al. B Cells and T follicular helper cells mediate response to checkpoint inhibitors in high mutation burden mouse models of breast cancer. Cell. 2019;179:1191–.e21.
pubmed: 31730857
pmcid: 6911685
doi: 10.1016/j.cell.2019.10.028
Cui C, Wang J, Fagerberg E, Chen PM, Connolly KA, Damo M, et al. Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses. Cell. 2021;184:6101–.e13.
pubmed: 34852236
pmcid: 8671355
doi: 10.1016/j.cell.2021.11.007
Lu Y, Zhao Q, Liao JY, Song E, Xia Q, Pan J, et al. Complement signals determine opposite effects of B cells in chemotherapy-induced immunity. Cell. 2020;180:1081–.e24.
pubmed: 32142650
doi: 10.1016/j.cell.2020.02.015
Meylan M, Petitprez F, Becht E, Bougoüin A, Pupier G, Calvez A, et al. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity. 2022;55:527–41.e5.
Biswas S, Mandal G, Payne KK, Anadon CM, Gatenbee CD, Chaurio RA, et al. IgA transcytosis and antigen recognition govern ovarian cancer immunity. Nature. 2021. https://doi.org/10.1038/s41586-020-03144-0 .
Viant C, Weymar GHJ, Escolano A, Chen S, Hartweger H, Cipolla M, et al. Antibody affinity shapes the choice between memory and germinal Center B cell fates. Cell. 2020; S0092867420313040. https://doi.org/10.1016/j.cell.2020.09.063 .
Mazor RD, Nathan N, Gilboa A, Stoler-Barak L, Moss L, Solomonov I, et al. Tumor-reactive antibodies evolve from non-binding and autoreactive precursors. Cell. 2022;185:1208–22.e21.
Hägglöf T, Cipolla M, Loewe M, Chen ST, Mesin L, Hartweger H, et al. Continuous germinal center invasion contributes to the diversity of the immune response. Cell. 2023;186:147–.e15.
pubmed: 36565698
doi: 10.1016/j.cell.2022.11.032
Phad GE, Pinto D, Foglierini M, Akhmedov M, Rossi RL, Malvicini E, et al. Clonal structure, stability and dynamics of human memory B cells and circulating plasmablasts. Nat Immunol. 2022;23:1–10.
doi: 10.1038/s41590-022-01230-1
Pfreundschuh M. The genealogy of SEREX. Cancer Immunol. 2012;12:7.
Tang Z-M, Ling Z-G, Wang C-M, Wu Y-B, Kong J-L. Serum tumor-associated autoantibodies as diagnostic biomarkers for lung cancer: a systematic review and meta-analysis. PLOS ONE. 2017;12:e0182117.
pubmed: 28750095
pmcid: 5547718
doi: 10.1371/journal.pone.0182117
Gu Y, Liu Y, Fu L, Zhai L, Zhu J, Han Y, et al. Tumor-educated B cells selectively promote breast cancer lymph node metastasis by HSPA4-targeting IgG. Nat Med. 2019;25:312–22.
pubmed: 30643287
doi: 10.1038/s41591-018-0309-y
Overacre-Delgoffe AE, Bumgarner HJ, Cillo AR, Burr A, Tometich JT, Bhattacharjee A, et al. Microbiota-specific T follicular helper cells drive tertiary lymphoid structures and anti-tumor immunity against colorectal cancer. Immunity. 2021;54:2812–.e4.
pubmed: 34861182
pmcid: 8865366
doi: 10.1016/j.immuni.2021.11.003
Liu W, Tai CT, Liu X, Pastan I. Anti-mesothelin immunotoxin induces mesothelioma eradication, anti-tumor immunity, and the development of tertiary lymphoid structures. Proc Natl Acad Sci USA. 2022;119:e2214928119.
Akbar R, Robert PA, Pavlović M, Jeliazkov JR, Snapkov I, Slabodkin A, et al. A compact vocabulary of paratope-epitope interactions enables predictability of antibody-antigen binding. Cell Rep. 2021;34:108856.
pubmed: 33730590
doi: 10.1016/j.celrep.2021.108856
Setliff I, Shiakolas AR, Pilewski KA, Murji AA, Mapengo RE, Janowska K, et al. High-throughput mapping of B cell receptor sequences to antigen specificity. Cell. 2019;179:1636–.e15.
pubmed: 31787378
pmcid: 7158953
doi: 10.1016/j.cell.2019.11.003
Denton AE, Innocentin S, Carr EJ, Bradford BM, Lafouresse F, Mabbott NA, et al. Type I interferon induces CXCL13 to support ectopic germinal center formation. J Exp Med. 2019;216:621–37.
pubmed: 30723095
pmcid: 6400543
doi: 10.1084/jem.20181216
Asrir A, et al. Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy. Cancer Cell. 2022. S1535610822000046. https://doi.org/10.1016/j.ccell.2022.01.002 .
Shi J, Hou S, Fang Q, Liu X, Liu X, Qi H. PD-1 controls follicular T helper cell positioning and function. Immunity. 2018;49:264–.e4.
pubmed: 30076099
pmcid: 6104813
doi: 10.1016/j.immuni.2018.06.012
Herati RS, Knorr DA, Vella LA, Silva LV, Chilukuri L, Apostolidis SA, et al. PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine. Nat Immunol. 2022;23:1183–92.
pubmed: 35902637
pmcid: 9880663
doi: 10.1038/s41590-022-01274-3
Lee J, Paparoditis P, Horton AP, Frühwirth A, McDaniel JR, Jung J, et al. Persistent antibody clonotypes dominate the serum response to influenza over multiple years and repeated vaccinations. Cell Host Microbe. 2019;25:367–e5.
pubmed: 30795981
pmcid: 6417944
doi: 10.1016/j.chom.2019.01.010